

Impacting Morbidity & Mortality in Patients with COPD: Optimal Use of Drug Therapy

Jake Nichols, PharmD, MBA, BCPS
Director of Clinical Affairs
Commonwealth Medicine
UMass Medical School

References

- Global Initiative for Chronic Obstructive Lung Disease (“GOLD”), NIH pub. #2701A; 2006.
- Mannino et al. COPD disease surveillance—United States, 1971-2000 *MMWR*. 2002;51(SS-6):1-16.
- Petty, T. COPD in Perspective. *CHEST* 2002;121:116S-120S.
- NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease. April 2001; (Updated 2006).
- American Thoracic Society Statement Statement. *Am J Respir Crit Care Med*. 1995;152(suppl 5):S77-S120.
- Barnes PJ. Chronic obstructive pulmonary disease. *N Engl J Med*. 2000;343:269-280.
- American Thoracic Society Statement. *Am J Respir Crit Care Med*. 1995;152(suppl 5):S77-S120.
- NLHEP. *Chest*. 1998;113(suppl 2):123S-163S.
- Haas F, Axen K. *Pulmonary Therapy and Rehabilitation: Principles and Practise*. 2nd ed. Baltimore, Md: Williams & Wilkins; 1991.
- Petty L, Enright PL. *Simple office spirometry for primary care practitioners*.
- Mahler DA et al. *Chest*. 1999;115:957-965.
- Dahl R et al. *Am J Respir Crit Care Med*. 2001;164:778-784.
- van Noord JA, de Munck DR, Bantje TA, et al. *Eur Resp J*. 2000;15:878-885.
- Barnes PJ. *Managing Chronic Obstructive Pulmonary Disease*, 2nd ed. London: Scientific Press Limited.; 2001.
- Combivent Inhalation Aerosol Study Group. *Chest*. 1994.
- Disse B et al. *Life Sci* (1999).
- Casaburi R., et. Al. *ERJ* 2002; 19:217-224.
- Vincken W., et. Al, *ERJ* 2002; 19:209-216.
- Donohue J, et. Al, *Chest* 2002; 122:47-55.
- Tashkin DP and Cooper CB. The role of long-acting bronchodilators in the management of stable COPD. *Chest* 2004; 125:249-259.
- Anthonisen NR et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. *Ann Intern Med*. 1987.
- Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. *Chest*. 2000.
- Brusasco V, et. Al, *Thorax* 2003; 58:399-404.
- Lloberes et al. *Eur Respir J*. 1988; 1:536-539.
- P Almagro et al, *Chest* 2002; 121:1441-1448.
- van Noord JA, de Munck DRAJ, Bantje ThA, et al. *Eur Respir J*. 2000;15:878-885.

- Friedman M, Serby CW, Menjoge SS, et al. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. *Chest*. 1999;115:635-641.
- Hanania NA, et al. (2003). The efficacy and safety of fluticasone propionate (250 micrograms)/salmeterol (50 micrograms) combined in the Diskus Inhaler for the treatment of COPD. *Chest*, 124: 834–843.
- Calverley P, et al. (2003). Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: A randomised controlled trial. *Lancet*, 361: 449–456.
- Kardos P, et al "Impact of Salmeterol/Fluticasone Propionate versus Salmeterol on Exacerbations in Severe Chronic Obstructive Pulmonary Disease" *Am J Respir Crit Care Med* 2007; 175:144-149.
- Niewoehner DE, Wilt TJ "Inhaled Corticosteroids for Chronic Obstructive Pulmonary Disease: A Status Report" *Am J Respir Crit Care Med* 2007; 175:103-104.
- Calverley et al. Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease. *NEJM* 2007; 356:775-89.